Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Expands By 1,863.4%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totaling 3,408,880 shares, an increase of 1,863.4% from the December 31st total of 173,618 shares. Approximately 3.1% of the shares of the stock are short sold. Based on an average daily volume of 41,428,043 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 41,428,043 shares, the short-interest ratio is presently 0.1 days. Approximately 3.1% of the shares of the stock are short sold.

Institutional Trading of China SXT Pharmaceuticals

An institutional investor recently bought a new position in China SXT Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 48,759 shares of the company’s stock, valued at approximately $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Performance

SXTC opened at $0.10 on Wednesday. China SXT Pharmaceuticals has a 52-week low of $0.08 and a 52-week high of $7.84. The business has a fifty day moving average of $1.13 and a 200 day moving average of $1.40.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings data on Wednesday, December 31st. The company reported ($0.03) EPS for the quarter. The business had revenue of $0.31 million during the quarter.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.